"10.1371_journal.pone.0041006","plos one","2012-07-18T00:00:00Z","Vincent Thomas; Ana Góis; Bruce Ritts; Peter Burke; Thomas Hänscheid; Gerald McDonnell","STERIS SA R&D, Fontenay-aux-Roses, France; Unidade de Microbiologia Molecular e Infecção, Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Lisbon, Portugal; STERIS Corporation, St. Louis, Missouri, United States of America; STERIS Corporation, Mentor, Ohio, United States of America; STERIS Limited, Basingstoke, United Kingdom","Conceived and designed the experiments: GM PB VT TH. Performed the experiments: VT AG. Analyzed the data: GM BR VT AG TH. Contributed reagents/materials/analysis tools: PB GM. Wrote the paper: VT AG TH.","VT, BR, PB and GMcD are employees of STERIS Corporation. A patent disclosure has been submitted by STERIS for the use of IFDOs as a tool to screen treatments efficacy against prion and other misfolded proteins but there is currently no commercial application. (USA patent: McDonnell, G. Antloga, K. In Vitro Model of Priocidal Activity. US Patent No: 7,129,080 B2. October 31st 2006). There are no further products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2012","07","Vincent Thomas","VT",6,TRUE,4,2,5,3,TRUE,TRUE,FALSE,0,NA,FALSE
